Headache and Migraine

Zavegepant joins other CGRP antagonists as an option for individuals experiencing migraine.

Study results add to the body of evidence demonstrating the efficacy of CGRP inhibitors for migraine treatment and prophylaxis.

Patients using the treatment reported reduced headache intensity and better quality of life.

Only the 60 mg dose of atogepant is approved for chronic migraine prevention.

Vitamin D supplementation may be an effective and safe adjunctive prophylactic therapy to topiramate for children who experience migraine attacks, showed a study conducted in Saudi Arabia.

The spray, called Zavzpret, intends to help individuals who struggle with migraines but can't take oral medication because of nausea or vomiting

Nerivio received clearance in January 2021 for use in acute migraine.

Nearly 40 million people in the United States suffer from migraine, with the World Health Organization classifying migraine as 1 of the 10 most disabling medical illnesses.

The number of digital therapeutics available for migraine is likely to expand.

History of migraine may be associated with poor sleep in premenopausal and perimenopausal women, according to research presented at the North American Menopause Society Annual Meeting.

Survey results addressed connections between migraine and mental health, stigma, and treatment preferences.

Understanding headaches and their various treatment options can help pharmacists counsel patients at the counter.

Current migraine care recommendations do not reflect recent advances in the scientific understanding of migraine disease.

Pharmacists can be a helpful resource in counseling patients about the acute treatment of migraine. Patients often have questions about the best options for treating a migraine attack.

Migraines can be disabling for those affected, but various pharmacologic and nonpharmacologic therapies are available.

A recent study examined whether individuals with migraine are at increased risk of abdominal aortic aneurysm.

Migraine sufferers reported worsened symptoms during social distancing, which may be attributed to reduced sleep quality and physical activity.

Migraines are the leading cause of days lost due to disability, yet many individuals with migraines do not seek care.

The development of a new combination drug can be a more potent and safe therapy for migraine prophylaxis.

A study presented at the American Academy of Neurology’s 73rd Annual Meeting aimed to identify predictors of acute treatment optimization in individuals with migraine

Real-world data comparing erenumab with oral preventive medications was presented at the American Academy of Neurology’s 73rd Annual Meeting.

A study presented at the American Academy of Neurology’s 73rd Annual Meeting explored the fundamental barriers to good medical outcomes in migraine.

A 25-year study examines triptan use as an acute treatment strategy for migraines in a Danish population.

Experts discussed clinical questions regarding migraine treatments and COVID-19 vaccines.

Investigators offer a review of the most recent literature depicting the relationship between estrogen and the incidence of migraine headache.